Investigational Once-Weekly Oral ART Combination Effectively Maintains Viral Suppression In Adults With HIV-1 Through 24 Weeks, Study Finds

MedPage Today (7/16, Haelle) reports, “An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in adults with HIV-1 through 24 weeks, according to a phase IIb study.” In the study, “among participants with available data, all remained virologically suppressed with islatravir 20 mg and ulonivirine at dosages of 100 mg, 200 mg, or 400 mg.” The findings were presented at the International AIDS Society Conference on HIV Science.